Abstract 1194P
Background
Neuroendocrine tumors of the appendix are typically detected incidentally during appendectomy. A recent study reported no cases of metachronous metastases among patients with primary tumors <2cm, regardless of lymph node status or referral for completion hemicolectomy. However, questions persist regarding the possibility of metastases developing decades after surgery, particularly since appendiceal NETs are frequently diagnosed in young adults and children.We therefore sought to evaluate patients with metastatic appendiceal NETs to assess whether any had been diagnosed previously with an early stage appendiceal NET.
Methods
We analyzed a large institutional neuroendocrine tumor database to identify appendiceal NETs of all stages and ascertain whether any patients with localized tumors developed metastases, and whether any with metastatic disease had originally presented with an early-stage tumor.
Results
Out of over 5,000 patients seen in the neuroendocrine tumor clinic between 2008 and 2022, 95 were diagnosed with an appendiceal NET. Of these, only 6 patients (approximately 0.1% of total NET population) had stage 4 metastases, all diagnosed synchronously at time of initial diagnosis. All 6 patients had peritoneal disease. No patient with earlier-stage disease developed distant metastases.
Conclusions
Metastatic appendiceal NETs are exceptionally rare with a tendency to metastasize within the peritoneum. In all cases of stage 4 disease, metastases were observed at time of diagnosis. Our data provide further validation for the proposition that small local appendiceal NETs resected during appendectomy require no further surgery or surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Strosberg: Financial Interests, Personal, Speaker’s Bureau: Ipsen, Tersera; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13
1140P - Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
Presenter: Emilie Gerard
Session: Poster session 13
1141P - Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
Presenter: Elena Croce
Session: Poster session 13
1142P - Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems
Presenter: Marlies Wakkee
Session: Poster session 13
1143P - Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma
Presenter: Daniela Esposito
Session: Poster session 13
1144P - High-plex spatial profiling of cutaneous squamous cell carcinoma to identify biomarkers associated with clinical outcomes: The cMIC study
Presenter: Rahul Ladwa
Session: Poster session 13
1145P - Clinical characteristics and survival of patients with advanced Merkel cell carcinoma (MCC) treated with avelumab: Analysis of a prospective German MCC registry (MCC TRIM)
Presenter: Juergen Becker
Session: Poster session 13
1146P - Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
Presenter: Giovanni Grignani
Session: Poster session 13
1148P - Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
Presenter: Astrid Blom Fily
Session: Poster session 13